Annex 1 Case Studies and Practical Insights: Turning Expectations into Evidence at the 2026 ISPE Aseptic Conference
EU GMP Annex 1 has pushed sterile manufacturing conversations from “what does it mean?” to “how is it proven?” Annex 1 requires a facility-wide, integrated contamination control strategy (CCS) that defines critical control points, verifies the effectiveness of design and operational controls, and is actively reviewed to drive continual improvement.
The 2026 ISPE Aseptic Conference tracks Annex 1 Case Studies and Annex 1 Practical Insights are designed for that translation, from expectation to evidence, using real-world examples rather than abstract models.
Three Pain Points the Annex 1 Tracks Aim to Address
1) Turning the CCS into a living system rather than a static narrative
Many organizations can describe controls but still struggle to show traceability: where risks are controlled, how effectiveness is verified, what signals trigger action, and how learning feeds back into improvement. The urgency is heightened by Annex 1’s reminder that monitoring or testing alone does not give assurance of sterility. Assurance depends on appropriate design and procedures that continue to perform as intended.
In today’s environment, where inspection teams increasingly ask to see the “connective tissue” between risk assessment, qualification, and ongoing verification, gaps in CCS can execution quickly become an operational pain.
2) Demonstrating barrier-system performance, especially around interventions and glove systems
Annex 1 states that restricted access barrier systems (RABS) or isolators are beneficial in minimizing contamination associated with direct human interventions in the critical zone, that their use should be considered in the CCS, and that alternative approaches should be justified.
It also sets clear expectations for critical zone protection. For open isolators, Grade A conditions with first air protection and unidirectional airflow sweeping over and away from exposed products are explicitly expected.
Glove systems remain a persistent pain point because they are both a barrier and an intervention pathway. Annex 1 expects isolator glove leak testing at defined intervals, generally at the minimum of the beginning and end of each batch or campaign, with additional testing as warranted.
That requirement becomes especially time sensitive as companies run shorter campaigns, expand product portfolios, and try to reduce manual interventions through barrier and automation strategies.
3) Managing operational variability that cascades into deviation burden and supply risk
Recurring issues (e.g., fill-weight deviations or first-of-kind qualifications) can generate high investigation load and complicate batch disposition. External pressures (lean staffing, shorter campaigns, and expanding product portfolios) make it harder to absorb repeated deviations without risking product supply. This is why practical stabilization lessons matter as much as design intent.
How the Annex 1 Tracks Address Key Annex 1 Implementation Challenges
The Annex 1 tracks are deliberately case study driven. Rather than re-stating Annex 1 expectations, sessions show how peers build defensible decisions and evidence packages under real constraints: legacy lines, limited shutdown windows, and cross-functional handoffs. Attendees can expect practical learning on:
- Structuring CCS content so it points directly to qualification outputs, trending signals, and investigation triggers, consistent with Annex 1’s facility-wide CCS expectations
- Justifying barrier choices and demonstrating performance during technology transitions (including the long arc from RABS to isolators), using real examples rather than generic models
- Applying case-based problem-solving to the “messy middle” topics that can dominate risk: transfers, glove integrity, cleaning effectiveness, and first-of-kind qualification
Exciting Topics to Anticipate in the Annex 1 Tracks
Rapid Transport Port (RTP) Integrity Testing as a CCS Tool
Transfer points are frequently weak links because they bridge people, materials, and the Grade A boundary. A session presented by Giovanni Tronci, PhD, of Tema Sinergie on an innovative device and algorithm capable of testing RTP integrity treats transfer integrity as a measurable performance indicator rather than as an assumed design intent. This can provide professionals with a more practical toolkit for strengthening CCS arguments around transfers—which are often expected to be shown during inspections and deviation investigations.
Advancing SteamSterilized Isolator Qualification
A firstofitskind steamsterilized isolator has been engineered and qualified to enable insitu sterilization of indirect product contact components through an integrated clean-in-place/steam-in-place approach, eliminating offline autoclaving and improving aseptic handling of high-mass items. A session presented by Geert Vandenbossche, PhD, of C&E Solutions BV, will detail the isolator’s dynamic pressure-balancing architecture, which maintains controlled differentials across chambers throughout all sterilization phases. Integrity testing of gaskets, silicone membranes was guaranteed and the steam-sterilized diffuser confirmed unidirectional flow—providing a robust, streamlined method for sterilizing indirect product contact components.
Challenges with Implementing Annex 1 at the Global Level: When One Standard Meets Many Realities
Many companies are trying to implement Annex 1 expectations across networks that span different regulatory agencies, legacy facility designs, supplier bases, and quality cultures. Even when the intent is clear, execution can be uneven in terms of aligning what “good” looks like across sites, deciding when local practices are truly equivalent, and managing gaps between global standards and site constraints without creating perpetual exceptions.
This session from Franck Bure of Genentech/Roche focuses on those real-world obstacles: how programs lose consistency across sites, where alignment typically breaks down, and what governance approaches can help maintain a common Annex 1 standard while allowing justified local differences.
Return on Investment: What Attendees Can Share with Their Teams
The Annex 1 tracks focus on practitioner-level problem-solving through case studies on global Annex 1 implementation, making aspirational “dream lines” compliant, reducing fill-weight deviations in practice, and qualifying a first steam-sterilized unit.
Attendees who attend the 2026 ISPE Aseptic Conference will gain insights into how to:
- Strengthen transfer controls with practical integrity testing approaches, including how to structure testing approaches, set acceptance criteria, and use results to support qualification, trending, and deviation investigations.
- Manage barrier technology evolution with defensible evidence, including how risk profiles may shift, what new failure modes emerge, and how qualification data supports inspection scrutiny.
- Apply practical deviation-reduction methods, such as those discussed for reducing fill-weight deviations, so that operational stability becomes an explicit part of contamination control rather than a separate operational workstream.
For sterile manufacturers balancing inspection readiness with supply reliability, these Annex 1-focused tracks aim to translate Annex 1 expectations into repeatable, defensible practice through the kind of detailed, experience-based learning that is difficult to find elsewhere.
